End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40.21 CNY | -2.71% | -3.36% | -7.65% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.04 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.65% | 377M | - | ||
+12.05% | 126B | A- | ||
-9.24% | 10.89B | A- | ||
+0.29% | 9.02B | C | ||
+36.99% | 5.41B | B+ | ||
-21.98% | 4.6B | C | ||
+8.02% | 3.44B | C- | ||
-10.32% | 2.74B | B- | ||
-12.33% | 2.06B | - | - | |
-13.53% | 1.96B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301033 Stock
- Ratings Medprin Regenerative Medical Technologies Co., Ltd.